Crossject is using its world-leading needle-free injection system, ZENEO™ to develop an attractive pipeline of high value SUPERGENERICS or New Therapeutics Entities. These products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort. Crossject’s first ZENEO® SUPERGENERIC product is expected to reach the market in 2015.

Crossject’s needle-free, pre-filled, single-use & fixed dose ZENEO ™ injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that ZENEO™ can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. Outside its own portfolio of SUPERGENERICS , Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

Crossject has been able to develop its world leading ZENEO® injection system through collaborations with a range of leading research companies including SNPE and Hirtenberger, both of which are experts in propulsion.

Statements contained in this material, particularly those regarding the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments,
growth of the organization making this presentation, industry growth or other trend projections and any estimated company earnings are or may be forward looking statements and as such involve risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these statements depending on a variety of factors.

This material is presented by NASDAQ who make no representation or warranty regarding the accuracy or liability or completeness of any information provided and any reliance you place on such information will be at your sole risk.

Company
details

CROSSJECT

Crossject is using its world-leading needle-free injection system, ZENEO™ to develop an attractive pipeline of high value SUPERGENERICS or New Therapeutics Entities. These products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort. Crossject’s first ZENEO® SUPERGENERIC product is expected to reach the market in 2015.

Crossject’s needle-free, pre-filled, single-use & fixed dose ZENEO ™ injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that ZENEO™ can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. Outside its own portfolio of SUPERGENERICS , Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

Crossject has been able to develop its world leading ZENEO® injection system through collaborations with a range of leading research companies including SNPE and Hirtenberger, both of which are experts in propulsion.